等待開盤 09-17 09:30:00 美东时间
-0.080
-3.77%
今日重点评级关注:Ascendiant Capital:维持Outlook Therapeutics"买入"评级,目标价从10美元升至10.5美元;摩根士丹利:维持Aurora Innovation"超配"评级,目标价从14美元升至18美元
09-14 16:05
Under the agreement, the Company received initial funding at closing, with future tranches available upon achieving certain milestones. The financing is intended to support the scale-up of the Company’s proprietary laboratory-developed tests, particularly its CNSide® cerebrospinal fluid ("CSF") assa...
09-10 19:17
As earnings season ends, investors are turning to updated Quant ratings to see how companies stack up after their latest results. These ratings grade stocks on key metrics like value, growth, profits,...
09-01 22:25
Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial shows strong safety signal CNSide® cost-of-care analysis shows up to 47% reductio...
08-20 19:36
Cerenome (NASDAQ:CNSY) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(0.85) by 54.12 percent. This is a 718.75 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $411.000 thousand ...
08-15 05:12